After a boom in 2025, health tech and AI startups are facing a market recalibration as investors and enterprise buyers demand measurable ROI. Companies that cannot demonstrate tangible cost savings, efficiency gains, or sticky enterprise adoption are seeing longer sales cycles, fundraising challenges, and increasing pressure to consolidate or be acquired. The reset rewards startups with demonstrable impact while weeding out speculative plays. This shift sets the stage for a more sustainable and outcome-driven innovation landscape in 2026.